Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CAO Christopher Paul German sold 344 shares of the firm's stock in a transaction dated Friday, March 21st. The shares were sold at an average price of $54.23, for a total value of $18,655.12. Following the completion of the sale, the chief accounting officer now owns 2,889 shares of the company's stock, valued at approximately $156,670.47. This represents a 10.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Christopher Paul German also recently made the following trade(s):
- On Wednesday, February 19th, Christopher Paul German sold 635 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $57.22, for a total value of $36,334.70.
Rhythm Pharmaceuticals Price Performance
Shares of Rhythm Pharmaceuticals stock opened at $53.72 on Tuesday. The firm has a market cap of $3.40 billion, a PE ratio of -12.41 and a beta of 2.30. Rhythm Pharmaceuticals, Inc. has a 1 year low of $35.17 and a 1 year high of $68.58. The stock has a fifty day moving average price of $55.28 and a 200-day moving average price of $54.99.
Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.03). The company had revenue of $41.83 million during the quarter, compared to the consensus estimate of $38.48 million. Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. As a group, equities analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -4.32 EPS for the current fiscal year.
Wall Street Analyst Weigh In
RYTM has been the topic of a number of research reports. Stifel Nicolaus started coverage on Rhythm Pharmaceuticals in a research report on Wednesday, March 5th. They set a "buy" rating and a $78.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of Rhythm Pharmaceuticals in a report on Thursday, January 2nd. They set a "buy" rating and a $80.00 price objective on the stock. Oppenheimer began coverage on shares of Rhythm Pharmaceuticals in a report on Friday, December 20th. They set an "outperform" rating and a $76.00 price objective for the company. Needham & Company LLC upped their target price on shares of Rhythm Pharmaceuticals from $64.00 to $66.00 and gave the stock a "buy" rating in a report on Tuesday, March 18th. Finally, Morgan Stanley reiterated an "overweight" rating and set a $72.00 price target on shares of Rhythm Pharmaceuticals in a research note on Friday, March 7th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $69.46.
View Our Latest Analysis on RYTM
Hedge Funds Weigh In On Rhythm Pharmaceuticals
Several institutional investors have recently bought and sold shares of the company. Castleark Management LLC increased its position in Rhythm Pharmaceuticals by 1.3% in the third quarter. Castleark Management LLC now owns 19,260 shares of the company's stock worth $1,009,000 after buying an additional 250 shares during the last quarter. Two Sigma Advisers LP increased its holdings in Rhythm Pharmaceuticals by 2.3% in the 4th quarter. Two Sigma Advisers LP now owns 13,100 shares of the company's stock worth $733,000 after acquiring an additional 300 shares during the last quarter. SRS Capital Advisors Inc. raised its stake in Rhythm Pharmaceuticals by 740.7% in the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company's stock valued at $25,000 after acquiring an additional 400 shares during the period. Raleigh Capital Management Inc. bought a new stake in Rhythm Pharmaceuticals in the 4th quarter valued at about $28,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Rhythm Pharmaceuticals by 2.0% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,156 shares of the company's stock valued at $1,857,000 after purchasing an additional 654 shares during the last quarter.
Rhythm Pharmaceuticals Company Profile
(
Get Free Report)
Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
